Nutriband Chairman to Present at NobleCon21, Highlighting Abuse-Deterrent Transdermal Technology

Nutriband Inc. has announced that Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference. The presentation is scheduled for December 3 at 9:30 a.m. Eastern Time at Florida Atlantic University's Executive Education Complex in Boca Raton, Florida. Investors and conference guests may attend at a discounted rate using code NTRBNOBLECON. For those unable to attend in person, a high-definition webcast will be available the following day at nobleconference.com and Channelchek.com, where it will remain archived for 90 days. The full press release detailing the announcement can be viewed at https://nnw.fm/Bx5x3.

The company is primarily engaged in developing a portfolio of transdermal pharmaceutical products. Nutriband's lead product under development is an abuse-deterrent fentanyl patch incorporating its proprietary AVERSA technology. This technology represents a significant advancement in transdermal drug delivery systems, designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. AVERSA technology can be incorporated into any transdermal patch, offering broad application potential across multiple pharmaceutical products that carry abuse risks. The technology's development comes at a critical time when opioid abuse remains a serious public health concern in the United States and globally.

Investors following Nutriband can access the latest news and updates relating to NTRB in the company's newsroom at https://nnw.fm/NTRB. The company maintains its corporate website at www.nutriband.com, though the company notes that any material contained in or derived from its websites is not part of the official press release. The presentation at NobleCon21 provides an opportunity for the company to showcase its technology platform and business strategy to the investment community. Emerging growth equity conferences like NobleCon21 serve as important venues for companies to communicate their value proposition and growth potential directly to potential investors and financial analysts.

This announcement matters because it highlights a company at the intersection of pharmaceutical innovation and public health. With opioid abuse continuing to pose significant challenges, technologies like AVERSA that aim to deter abuse in transdermal delivery systems are of paramount importance. The presentation allows Nutriband to demonstrate how its proprietary technology could mitigate risks associated with potent drugs like fentanyl, potentially reducing incidents of overdose and misuse. For the investment community, the event offers insight into a niche but critical segment of the healthcare market focused on safety-enhanced drug delivery.

The implications of this announcement extend beyond corporate visibility. Successfully commercializing abuse-deterrent technologies could influence regulatory approaches and prescribing practices, encouraging safer use of opioids in pain management. For Nutriband, effective communication at conferences like NobleCon21 is crucial for securing funding and partnerships necessary to advance clinical development and navigate the complex pharmaceutical landscape. The archived webcast ensures broader accessibility, allowing stakeholders to evaluate the company's progress and the technology's market potential over time.